Titlebook: Small Molecules in Hematology; Uwe M. Martens Book 2018Latest edition Springer International Publishing AG, part of Springer Nature 2018 S

Insufficient

COKE

Dasatinib,ultiple other kinases, including c-KIT, PDGFR-. PDGFR-., and ephrin receptor kinases. Dasatinib is a very potent inhibitor of BCR-ABL and an effective treatment for the BCR-ABL-driven diseases chronic myeloid leukemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ ALL),

初学者

Inflamed

Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor,tion of Src and ABL kinase and also targeting further kinases, it creates a unique target portfolio which also explains its unique side effect profile. The approval of bosutinib in 2013 made the drug available for patients previously treated with one or more tyrosine kinase inhibitor(s) and for whom

Bravura

Ponatinib: A Third-Generation Inhibitor for the Treatment of CML,nce against the drug, the development of new inhibitors was promoted. This led to the second-generation inhibitors dasatinib, nilotinib, and bosutinib. Despite all achieved improvements, first- and second-generation inhibitors are ineffective against the BCR-ABL T315I “gatekeeper” mutation. In order

seduce

MIRTH

Ibrutinib, role in BCR signalling. Ibrutinib (PCI-32765) is a small molecule which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency. Ibrutinib is currently approved by the FDA and EMA for use in chronic lymphocytic leukaemia in any line of tr

束缚

guzzle

骚动

Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytolet derived-, and fibroblast growth factor receptor, stem cell factor receptor c-KIT, as well as mutated and wild-type FLT3 kinases. Midostaurin was approved by the Food and Drug Administration (FDA) and the European Medical Agency (EMA) for acute myeloid leukemia with activating . mutations in comb